{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:06:34Z","timestamp":1789009594766,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019518","name":"Eli Lilly Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cjco.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:39:19Z","timestamp":1781714359000},"page":"1198-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rationale and Design of the Canadian Lipoprotein(a) Registry"],"prefix":"10.1016","volume":"8","author":[{"given":"Adam I.","family":"Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Abdel-Qadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Bollu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomira","family":"Cermakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Fordyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Moulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Roston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Iatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3686-3807","authenticated-orcid":false,"given":"Liam R.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2026.06.003_bib1","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjco.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.06.003_bib3","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.06.003_bib4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.06.003_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.06.003_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.06.003_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjco.2026.06.003_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.06.003_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cjco.2026.06.003_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.06.003_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON Trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjco.2026.06.003_bib13","unstructured":"Olpasiran Trials of Cardiovascular Events and Lipoprotein (a) Reduction (OCEAN(a))---Outcomes Trial. ClinicalTrials.gov identifier: NCT05581303. Updated November 12, 2024. Accessed June 4, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05581303."},{"key":"10.1016\/j.cjco.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran---a long-duration small interfering RNA targeting lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.06.003_bib15","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran---a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.06.003_bib16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.06.003_bib17","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjco.2026.06.003_bib18","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.06.003_bib20","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.46747\/cfp.6910675","article-title":"PEER simplified lipid guideline 2023 update: prevention and management of cardiovascular disease in primary care","volume":"69","author":"Kolber","year":"2023","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.cjco.2026.06.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100478","article-title":"Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes","volume":"14","author":"Kelsey","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120458","article-title":"Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort study","volume":"408","author":"Manivong","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjco.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1016\/j.jacl.2024.07.012","article-title":"Attitudes and barriers to lipoprotein(a) testing: a survey of providers at the University of Pennsylvania Health System","volume":"18","author":"D'Souza","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjco.2026.06.003_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOL.0000000000000982","article-title":"The need for national and international registries of patients with elevated lipoprotein(a)","volume":"36","author":"Kramer","year":"2025","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjco.2026.06.003_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035610","article-title":"Lipoprotein (a) testing in patients with atherosclerotic cardiovascular disease in 5 large US health systems","volume":"13","author":"Shah","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.06.003_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf342","article-title":"Rationale for the routine screening of lipoprotein (a) in cardiovascular risk assessment [e-pub ahead of print]","author":"Iatan","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib29","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.06.003_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1373\/clinchem.2017.279422","article-title":"Imputation of baseline LDL cholesterol concentration in patients with familial hypercholesterolemia on statins or ezetimibe","volume":"64","author":"Ruel","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.cjco.2026.06.003_bib31","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/CIRCULATIONAHA.118.035658","article-title":"Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction","volume":"139","author":"Khera","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.06.003_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ehjci\/jew335","article-title":"Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"18","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjco.2026.06.003_bib33","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0b013e3182181529","article-title":"The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association","volume":"123","author":"Bufalino","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.06.003_bib34","first-page":"326","article-title":"The British Columbia Familial Hypercholesterolemia Registry","volume":"55","author":"Wong","year":"2013","journal-title":"BCMJ"},{"key":"10.1016\/j.cjco.2026.06.003_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.atherosclerosis.2018.05.040","article-title":"Familial hypercholesterolemia in Canada: initial results from the FH Canada National Registry","volume":"277","author":"Brunham","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjco.2026.06.003_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjco.2026.06.003_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5339\/gcsp.2015.33","article-title":"The Copenhagen City Heart Study (Osterbroundersogelsen)","volume":"2015","author":"Aguib","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.cjco.2026.06.003_bib38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/clinchem\/45.7.1039","article-title":"Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study","volume":"45","author":"Seman","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.cjco.2026.06.003_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014711","article-title":"Risks of incident cardiovascular disease associated with concomitant elevations in lipoprotein(a) and low-density lipoprotein cholesterol---the Framingham Heart Study","volume":"9","author":"Afshar","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.06.003_bib40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.06.003_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosissup.2017.05.006","article-title":"Current insights into the German Lipoprotein Apheresis Registry (GLAR)---almost 5 years on","volume":"30","author":"Schettler","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.cjco.2026.06.003_bib42","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjco.2026.06.003_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/clc.23456","article-title":"Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: design and rationale of the Mass General Brigham Lp(a) Registry","volume":"43","author":"Berman","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034493","article-title":"Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the Mass General Brigham Lp(a) Registry","volume":"13","author":"Shiyovich","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.06.003_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035353","article-title":"Sex differences in the association between lipoprotein(a) and cardiovascular outcomes: the MGB Lp(a) Registry","volume":"14","author":"Kaur","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjco.2026.06.003_bib47","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.06.003_bib48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pcad.2024.08.004","article-title":"The prevalence, patients' characteristics, and hyper-Lp(a)-emia risk factors in the Polish population. The first results from the PMMHRI-Lp(a) Registry","volume":"86","author":"Sosnowska","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cjco.2026.06.003_bib49","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.5114\/aoms\/188294","article-title":"Lipoprotein(a) and its impact on cardiovascular disease---the Polish perspective: design and first results of the Zabrze-Lipoprotein(a) Registry","volume":"20","author":"Dyrbus","year":"2024","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.cjco.2026.06.003_bib50","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00392-024-02427-0","article-title":"Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients---results from a large-scale multicentre registry in Germany","volume":"115","author":"Altmann","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib51","first-page":"867","article-title":"Clinical care for patients with elevated lipoprotein(a) level in Canada: a practical framework for screening, risk assessment, and management","volume":"42","author":"Thanassoulis","year":"2026","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.06.003_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100315","article-title":"Estimating the prevalence of hypercholesterolemia in Indigenous populations: a systematic review and meta-analysis","volume":"2","author":"McCallum","year":"2023","journal-title":"JACC Adv"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26002258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26002258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:20:46Z","timestamp":1789006846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X26002258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589790X26002258"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2026.06.003","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and Design of the Canadian Lipoprotein(a) Registry","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}